Elanco Secures FDA Emergency Use Authorization for Credelio in Dogs

The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Elanco Animal Health for its product Credelio (active ingredient: lotilaner). This authorization allows the treatment of New World screwworm in dogs, a serious condition that can lead to severe health issues.

Credelio was previously approved as a chewable tablet designed to control fleas and ticks. The FDA’s decision comes after a study demonstrated the efficacy of lotilaner against the New World screwworm, a parasitic infestation that poses significant risks to canine health. This new authorization expands the uses of Credelio, highlighting its critical role in veterinary medicine.

Significance of the Authorization

The New World screwworm, scientifically known as Cochliomyia hominivorax, is a fly species that can cause devastating wounds in animals. The larvae of this fly feed on the tissues of living hosts, leading to severe infection and potential mortality if untreated. By allowing the use of Credelio for this purpose, the FDA aims to provide a vital tool for veterinarians facing this serious threat.

Elanco’s Credelio has already established a strong presence in the market as an effective solution for parasite control. The FDA’s rapid response in granting EUA underscores the urgency of addressing this emerging health concern in dogs.

Future Implications for Veterinary Care

Veterinarians and pet owners can now utilize Credelio as part of their treatment protocols for dogs affected by New World screwworm. This development is particularly important in regions where the screwworm is prevalent, and timely intervention is essential to prevent severe health complications.

The rapid development and approval process for Credelio’s new application reflect the ongoing commitment of both Elanco and regulatory agencies to ensure animal health and welfare. As veterinary professionals incorporate this treatment into their practices, it is expected to have a significant impact on managing and preventing screwworm infestations in dogs.

In summary, the FDA’s Emergency Use Authorization for Elanco’s Credelio marks a pivotal moment in combating New World screwworm in dogs. With its proven efficacy in parasite control and now in addressing this critical health threat, Credelio is set to enhance veterinary care and improve outcomes for affected dogs.